What happened
Shares of Innate Pharma (NASDAQ:IPHA) were soaring 19.5% higher as of 11:10 a.m. EST on Thursday. The big gain came after the company announced earlier in the day that the European Medicines Agency (EMA) has accepted the regulatory filing for Lumoxiti, a drug to treat hairy-cell leukemia (HCL).
So what
Lumoxiti won Food and Drug Administration approval in September 2018 as a treatment for relapsed or refractory HCL. The EMA's acceptance of the Marketing Authorization Application for the drug is a major step for Innate in potentially expanding theglobal marketfor its flagship product. If it wins EMA approval, Lumoxiti would become the first new relapsed or refractory HCL treatment in more than two decades.
Image source: Getty Images.
The news marked yet another milestone for Innate in recent months. In September 2019, the drugmaker and its big partner AstraZeneca (NYSE: AZN) announced plans to advance experimental drug monalizumab in combination with Erbitux to a late-stage clinical study targeting the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Innate also conducted an initial public offering (IPO) on the Nasdaq exchange in October.
Now what
Innate now must wait to see if Lumoxiti wins EMA approval. The company will also have to secure reimbursement for the drug (assuming it obtains approval) on a country-by-country basis in Europe.
Investors in biotech stocks are always looking for what's next. For Innate, the primary thing to watch other than what happens with Lumoxiti is the initiation of the late-stage study of monalizumab and Erbitux. Innate and AstraZeneca expect the clinical trial to begin this year.
10 stocks we like better than AstraZeneca
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AstraZeneca wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of December 1, 2019
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
